What’s next for diagnostic labs, a ‘bright spot’ during Covid-19?
What’s included? About the Author Reprints [email protected] Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. As U.S. diagnostic labs began confronting the Covid-19 pandemic in early March 2020, they faced monumental challenges to quickly build laboratory capacity. That included ramping up staffing and finding sources for the equipment and supplies needed to handle an unpredictable surge in the volume of Covid-19 testing.Despite the vital role that labs play in providing diagnostic information, they have been running lean shops for years with little ability to increase their daily testing capacity. This behavior was borne out of a need for financial stability, largely because commercial and federal insurers like Medicare and Medicaid have been paying labs less and less for the same testing since well before the pandemic. Log In | Learn More linkedin.com/in/lale-white-86307a11/ Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What’s next for diagnostic labs, a ‘bright spot’ during Covid-19? @XIFIN By Lâle White April 26, 2021 Reprints GET STARTED What is it? Opinions+ STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. INDRANIL MUKHERJEE/AFP via Getty Images Lâle White Tags diagnosticsSTAT+